CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a pioneer in regenerative cell-based therapies and devices, today announced that it has been enrolling patients in two Phase I clinical trials of the company’s first product, Vascugel™. The company’s Investigational New Drug (IND) application was successfully reviewed by the U.S. Food and Drug Administration (FDA) in May. The two clinical studies approved under the IND are evaluating the safety and feasibility of Vascugel™ for the maintenance of vascular patency after creation of arteriovenous (AV) access graft and AV fistula, respectively, for patients undergoing dialysis for the treatment of end-stage renal disease (ESRD).
